Francis Richard D 4

4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Mar 6, 2026

AI-generated summary of this filing

Updated Mar 6, 2026

TEVA CEO Richard D. Francis Sells Shares to Cover Taxes

What Happened

Richard D. Francis, President and CEO of Teva Pharmaceutical Industries Ltd. (TEVA), had restricted stock units vest and converted to shares on March 4, 2026. He sold 23,393 shares in open-market transactions at a weighted average price of $32.46, generating $759,442. The filing also shows the conversion/exercise of 50,223 derivative units and a grant of 136,736 restricted share units on the same date.
The sale was effected pursuant to a Rule 10b5-1 trading plan. The filing indicates additional shares were disposed at $0.00 (i.e., withheld/surrendered) in connection with tax withholding for the vested RSUs.

Key Details

Transaction date: March 4, 2026; Form 4 filed March 6, 2026 (timely).
Sale: 23,393 shares sold, weighted-average price $32.46, total proceeds $759,442 (range of individual sale prices: $32.095–$33.30).
Vesting/conversion: 50,223 RSUs converted/vested (reported as derivative exercise/conversion).
Grant: 136,736 restricted share units granted on March 4, 2026 (new RSU award).
Tax withholding: Filing shows shares disposed at $0.00 and a sale to cover tax obligations (footnote indicates shares were sold to cover taxes).
10b5-1 plan: Transactions were made pursuant to a pre-established Rule 10b5-1 trading plan.
Shares owned after the transactions: not specified in the provided filing details.

Context

These transactions reflect routine compensation vesting and associated tax-handling rather than an open-market investment bet. The RSU conversion and immediate partial sale/withholding to cover taxes is common: vested RSUs convert to shares, then some shares are sold or withheld to satisfy tax obligations.
The large RSU grant (136,736 units) vests over future years (footnotes describe scheduled vesting for portions in 2027–2030), so the grant is long-term compensation rather than an immediate cash purchase.

Form 4

Period: 2026-03-04

President and CEO

Transactions

Exercise/Conversion
Ordinary Shares
[F1][F2]
2026-03-04+50,223→ 1,171,605 total
Sale
Ordinary Shares
[F1][F3][F4][F5]
2026-03-04$32.46/sh−23,393$759,442→ 1,148,212 total
Exercise/Conversion
Restricted Share Units
[F2][F6][F1]
2026-03-04−50,223→ 100,446 total
→ Ordinary Shares (50,223 underlying)
Award
Restricted Share Units
[F2][F7][F1]
2026-03-04+136,736→ 136,736 total
→ Ordinary Shares (136,736 underlying)

Footnotes (7)

[F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
[F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
[F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2025.
[F4]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.095 to $33.30, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
[F6]Restricted share units were granted on March 4, 2024, with 50,223 vested on each of March 4, 2025 and March 4, 2026, and 50,223 vesting on each of March 4, 2027 and March 4, 2028.
[F7]Restricted share units were granted on March 4, 2026, with 34,184 vesting on each of March 4, 2027, March 4, 2028, March 4, 2029 and March 4, 2030.

Signature

/s/ Dov Bergwerk as attorney-in-fact for Richard D. Francis|2026-03-06

1 file